%0 Generic %A J., Bousquet %A C., Bachert %A G.W., Canonica %A J., Mullol %A Van Cauwenberge P. %A C.B., Jensen %A W.J., Fokkens %A J., Ring %A P., Keith %A G., Gopalan %D 2010 %T Supplementary Material for: Efficacy of Desloratadine in Persistent Allergic Rhinitis – A GA2LEN Study %U https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Efficacy_of_Desloratadine_in_Persistent_Allergic_Rhinitis_A_GA_sup_2_sup_LEN_Study/5121244 %R 10.6084/m9.figshare.5121244.v1 %2 https://ndownloader.figshare.com/files/8705701 %K Activity impairment %K ARIA %K Desloratadine %K Persistent allergic rhinitis %K Quality of life, rhinitis %K Randomized controlled trial %K Work productivity %X Background: The ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines proposed a classification for allergic rhinitis based on the duration of symptoms (intermittent or persistent) rather than on the time of allergen exposure (seasonal or perennial). There had been no placebo-controlled, randomized, clinical trial of desloratadine (DL) in patients with persistent allergic rhinitis to date. Objectives: To assess the efficacy and safety of DL in patients with persistent allergic rhinitis based on the ARIA classification. Methods: Patients 12 years of age and older with persistent allergic rhinitis were assessed over 85 days of treatment with DL 5 mg once daily (n = 360) or placebo (n = 356). The primary endpoint was the AM/PM reflective total 5-symptom score (T5SS) averaged over days 1–29. Secondary endpoints included AM/PM instantaneous T5SS and individual symptoms, therapeutic response, symptom severity assessed by a visual analogue scale and quality of life. Results: The mean reduction in AM/PM reflective T5SS was significantly greater with DL than placebo over days 1–29 (–3.76 vs. –2.87, p < 0.001) and on each individual day (p < 0.05). The mean AM instantaneous T5SS was significantly reduced with DL compared with placebo as early as day 2 (–1.90 vs. –1.46; p < 0.001). The therapeutic response and improvement in quality of life were significantly greater with DL than placebo (p < 0.001 for each). The frequency of treatment-related adverse events was low and similar between DL (10.0%) and placebo (8.4%). Conclusions: This study showed DL to be effective and safe in the treatment of persistent allergic rhinitis. %I Karger Publishers